Protocol Ledger

NCT05603143 · Phase III · TERMINATED

Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

Interventional Phase III clinical trial protocol NCT05603143 sponsored by Gilead Sciences in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-05 Enrollment: 468 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05603143
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)468 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05603143
Protocol FieldVerified Registry Value
NCT IdentifierNCT05603143
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment468 participants (ACTUAL)
Registered Start Date2022-11-05
WhyStopped ClassificationUnspecified

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI